References
- 1. Metra M, Ponikowski P, Beckenstein K et al. Advanced chronic heart failure: a position statement from the study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail. 2007, 9: 684-9410.1016/j.ejheart.2007.04.00317481947
- 2. Allen LA, Stevenson LW, Grady KL et al – Decesion making in advanced heart failure: a scientific statement from the American Heart Association, Circulation 2012, 125 (15): 1928-5210.1161/CIR.0b013e31824f2173389370322392529
- 3. Fang JC – Advanced (stage D) heart failure: a statement from the Heart Failure Society of America guidelines committee, J Card Fail 2015, 21 (6):519-34
- 4. Crespo-Leriro MG et al – Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology, Eur J Heart Fail. 2018, 20: 1505-153510.1002/ejhf.123629806100
- 5. Abonezzedine OF, Redfield MM – Who has advanced Heart Failure? Definition and epidemiology, Congest. Heart Fail 2011,17 4): 160-810.1111/j.1751-7133.2011.00246.x385775921790965
- 6. Metra M, Dinatolo E, Dasseni A – The New Hear Failure Association. Definition of Advanced Heart Failure, Cardiac Failure Rew 2019, 5(1): 5-810.15420/cfr.2018.43.1639606030847238
- 7. Fonarow GC, Yancy CW, hernandez AF et al – Potential impact of optional implementation of evidece-based heart failure therapy on mortality, Am Heart J 2011, 161(6):1024-3010.1016/j.ahj.2011.01.02721641346
- 8. Ginwalla M, Tofovic – Current status of inotropes in heart failure, Heart Failure Clin 2018,14: 601-61610.1016/j.hfc.2018.06.01030266368
- 9. Hashim T, Sanam K, Ravilla-Martinez et al – Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure, Circ Heart Failure 2015, 8:880-88610.1161/CIRCHEARTFAILURE.114.00177826179184
- 10. Rose EA, Gelinjns AC, Moskowitz AJ et al – Long term use of left ventricular assist device for end-stage heart failure. The Randomized Evaluation of the Mechanical Assistance the Treatment of Congestive Heart Failure (REMATCH) Study Group, N Engl J Med 2001, 345(20):1435-43
- 11. Rogers JG, Butler J, Lansman SL et al – Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial, J Am Coll Cardiol 2007, 50 (8) 241-710.1016/j.jacc.2007.03.06317707178
- 12. Brignole M, Auricchio A, Baron-Esquivias G et al – Guidelines on cardiac pacieng and cardiac resynchronization therapy: the Tark Force on Cardiac Pacing and Desyncronization Therapy of the European Society of Cardiologie (ESC). Developed in collaboration with the European heart Rhythm Association (EHRA), Eur Heart J 2013, 34: 2281-39210.1093/eurheartj/eht15023801822
- 13. Bariani G, Nesti M, Ziacchi M et al – Cardiac resyncronization on therapy: an Overview on Guidelines, Hear Fail Clin 2017, 13:117-23710.1016/j.hfc.2016.07.010
- 14. Abraham WT, Fisher WG, Smith AL et al – Cardiac resyncronization in chronic heart failure, N Engl J Med 2002, 376(24:1845-53
- 15. Linde C, Abraham WT, Gold MR et al – Randomized trial of resyncronization in midly symptomatic Heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure sumptoms, J Am Coll Card 2008,52:1834-4310.1016/j.jacc.2008.08.027
- 16.Mc Alister FA, Ezekowitz J – Cardiac resyncronization therapy for patients with left ventricular systolic disfunction, JAMA 2007,22: 2502-251410.1001/jama.297.22.2502
- 17. Frohlich GH, Holzmeister J, Hubler M et al – Prophylactic implantable carioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation, Heart 2013, 99:1158-116510.1136/heartjnl-2013-304185
- 18. Chaudhry Sunit-Preet, Stewart GC – Advanced Heart Failure: Prevalence, Natural Hystory and Prognostic, Heart Failure Clin 2016, 12:323-33310.1016/j.hfc.2016.03.001
- 19. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients, with reduce left ventricular efective fraction. The SOLVD Investigators, N Engl Med 1992, 327(10): 682-9110.1056/NEJM199209033271003
- 20. Greenberg B, Lottes SR, Nelson JJ et al – Predictors of clinical outcomes in patients given carvedilol for heart failure, Am J Cardiol 2006, 98 (1): 1480-410.1016/j.amjcard.2006.06.050
- 21. Corra U, Agostoni PG, Anker SD et al – Role of cardiopulmonary exercise test in clinical stratification in heart failure, Eur J Heart Fail. 2018, 20, 3-1510.1002/ejhf.979
- 22. Cacciatore F, Abete P, Mazzarella F et al – Fraily predicts log-term mortality in elderly subjects with chronic heart failure, Eur J Clin Invest 2005, 35 (12):723-3010.1111/j.1365-2362.2005.01572.x
- 23. DI Salvo TG, Mathier M, Semigran MJ et al – Preserved right ventricular ejection fraction predicts exercise capacity ane survival in advanced heart failure, J Am Coll Cardiol 1995, 25 (5): 1143-5810.1016/0735-1097(94)00511-N
- 24. Doust JA, Pietrzak E, Dobson A et al. How well does B-type natriuretic peptide predicts death and cardiac events in patients with heart failure: systematic review, BMJ 2005, 330(7492): 62510.1136/bmj.330.7492.625
- 25. Lee WH, Parker M – Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patiets with severe heart failure, Circulation 1986, 73(2): 257-6710.1161/01.CIR.73.2.257
- 26. Cutbert JJ, Pellicori P, Rigby et al – Low serum chloride in patients with chronic heart failure: clinical association and prognostic significance, Eur J Heart Fail 2018, 20:1426-3510.1002/ejhf.1247
- 27. Bock JS, Gottlich SS – Cardiorenal syndrome: new perspectives, Circulation 2010, 121 (23): 2592-60010.1161/CIRCULATIONAHA.109.886473
- 28 Kirklin JK, Naflel BC, Kormos RL et al – Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant, J Heart Lung Transplant 2013, 321 (21): 1205-1310.1016/j.healun.2013.09.001
- 29. Kiftleson M, Hurwitz S, Shah MR et al – Development of circulatory renal limitation to angiotensin-converting enzyma inhibitors identifies patients with severe heart failure and early mortality, J Am Coll Cardiol 2003, 41 ((11): 2029-3510.1016/S0735-1097(03)00417-0
- 30 Levy WC, Mozaffarian D, Linker DT et al – The Seattle Heart Failure model: predictor of survival in heart failure, Circulation 2006, 113 (11):1424-3310.1161/CIRCULATIONAHA.105.58410216534009
- 31. Rusinaru D, Tribouilloy C, Berry C et al – Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis: meta analysis global group in chronic heart failure (MAGGIC), Eur J Heart Fail 2013, 141 (10): 1139-46.10.1093/eurjhf/hfs09922782968
- 32. Wagas M, Cowger JA – Role of durable mechanical circulatory support for the management of advanced heart failure, Heart Fail clin 2013,12:399-40910.1016/j.hfc.2016.03.01227371516
- 33. Kirklin JK, Nashel DC, Pagani FD – Seventh INTERMACS annual report: a 15000 patients and counting, J Heart Lung Transplantation 2015, 34:1495-53410.1016/j.healun.2015.10.00326520247
- 34. Colvin-Adams M, Swith JM, Heubuer BM et al – OPTSRTR 2013 annual data report: Am J Transplant 2015, 15 (suppl 2)10.1111/ajt.1319925626345
- 35. Ponikowski P, Voor AA, Anker SD – Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Assocition (HFA) of the ESC, Eur. J Heart Failure 1016, 18:891-97510.1002/ejhf.592
- 36. Klein L, Dorobantu L – Mechanical Circulatory Support in Current Approach to Heart Failure - Eds Dorobantu L et al, Springer 2016; pag: 311-33310.1007/978-3-319-45237-1_15
- 37. Felman D, Pamboukian SV, Teuteberg I et al – The 2013 International Society for Heart and Lung Transplantation. Guidelines for mechanical circulatory support executive summary, J Heart Lung Transplant 2013, 22:157-82
- 38. Boyle AJ, Ascheim DD, Russo MJ et al – Clinical outcomes for continous flow left ventricular assist device patients stratified by pre-operative INTERMACS classification, J Heart Lung Transplant 2017, 30:402-40710.1016/j.healun.2010.10.01621168346
- 39. Jurda UP, Kushwaha SS, Tatooles AJ et al – Results of the destination therapy post-food and drug administration approval study with a continous flow left ventricular device : a prospective study using the INTERMACS Registry, J Am Coll Cardiol 2014, 63:1751-175710.1016/j.jacc.2014.01.05324613333
- 40. Kittleson MM – Changing role of Heart Transplantation, Heart Fail Clin 2016, 12:411-42110.1016/j.hfc.2016.03.00427371517
- 41. Kalmanovici I et al – Management of Advanced Heart Failure, Expert Rev. Cardiovasc. Therapy, 2013, 16(11); 775-79410.1080/14779072.2018.153011230282492
- 42. Melra MR, Canter CE, Hannan MM et al – The 2016 International Society of Heart Lung Transplantation listing criteria for heart transplantation: a 10 year up date, Heart Lung Transplant 2016, 75: 1-2310.1016/j.healun.2015.10.02326776864
- 43.Campbell RT, Petric MC, Jackson CE et al – Which patients with heart failure should receive specialist palleative care, Eur J Heart Fail. 2018, 20: 1338-4710.1002/ejhf.1240660747929952090